Exclusive Interviews

Yehuda Handelsman, MD, FACP, FACE, FNLA is an endocrinologist in private practice and Medical Director & Principal Investigator of the Metabolic Institute of America. He is a nationally and internationally recognized authority on Diabetes, Lipids, Obesity, HTN their  and the prevention of cardiovascular disease.

In this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about safely lowering A1c, safe LDL, the life-saving efficiency of some very expensive drugs, and exciting diabetes technology.

In part 1 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the reasoning behind changes to cholesterol goals.

In part 2 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the actual cost to the lives of patients who are put on more expensive, but life-saving, diabetes drugs.

In part 3 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about his LDL recommendations according to the patient and varying health events.

In part 4 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about safely lowering patient A1c to their particular goal without hypoglycemia.

In part 5 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the more exciting diabetes technology developments.

In part 6, the conclusion of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the ultimate good that came from the failure of Avandia.

In part 3 of this Exclusive Interview, Dr. Swapnil N Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about patient claims of hypoglycemia while on DPP4 treatment.

In part 2 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the ultimate savings in the use of DPP4s — reduced risk of hypoglycemia.